@LeftYahoo Check out this post of mine from 04/04/2020 where I laid out differences between ATHX and MESO pertaining to MAPCs vs MSCs.
https://hotcopper.com.au/threads/athersys-vs-mesoblast.5327521/?post_id=43874221
I also referenced the Khan and Newsome paper in that post.
I recall you asked about company literature regarding Mesoblast's Mesenchymal Lineage Cells (MLCs). Take a look at the link below. I don't expect much more info on MLCs that you can get from anyone else since they are proprietary to Mesoblast.
https://www.mesoblast.com/science/mesenchymal-lineage-cells
I am not sure if you are aware, in March 2016, Mesoblast acquired exclusively licensed patented technology developed at Harvard Med School which can modify MLCs to enhance their natural homing properties to sites of excessive inflammation. It is a proprietary cell targeting technology called ex vivo fucosylation.
As far as I know, no other company has this technology. Two thumbs up and a great advantage that Mesoblast has. I recall Mesoblast got this from Harvard for less than $5 million (don't quote me on that number but my communication with Mesoblast's Micahel Schuster at that time, as I recall, was around that $5 million mark). Pretty cheap for something so huge!
https://www.asx.com.au/asxpdf/20160317/pdf/435x8g7wvnnyr0.pdf
On a different note, Latin America is coming down hard with COVID-19. Mexico and Brazil in particular are near total collapse with their hospital systems due to the virus.
The Latin American market, which is usually ignored, is a huge market for Mesoblast, should REMESTEMCEL-L get approved.
To all the doubters: I will say this - read Mesoblast's PR from 05/13/2020 - here, I will quote the headline for you:
"MESOBLAST SUCCESSFULLY COMPLETES FINANCING TO SCALE-UP
MANUFACTURING OF REMESTEMCEL-L FOR COVID-19 ARDS".
With that headline, the company practically told us all that Remestemcel-L for COVID-19 induced ARDS will be approved by the FDA. If you cannot understand that headline you need to get your head examined.
Lastly - My humble request to all of you on this board is not to clutter the board with responding to Cato. Is is a request. Not a demand. As it is, this board has become very difficult to read these days. If clutter becomes rampant, you will likely see valuable posters stay away. I thought we got rid of madam-cancer, only now to be annoyed with the Cato syndrome.
- Forums
- ASX - By Stock
- MSB
- Analysis of the EAP
Analysis of the EAP, page-133
-
-
- There are more pages in this discussion • 938 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B |
Open | High | Low | Value | Volume |
$1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 39558 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 21776 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 39558 | 1.300 |
3 | 26433 | 1.295 |
6 | 108207 | 1.290 |
2 | 47468 | 1.285 |
3 | 10889 | 1.280 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 21776 | 3 |
1.315 | 57441 | 5 |
1.320 | 2500 | 1 |
1.325 | 61160 | 4 |
1.330 | 15000 | 2 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |